Reauthorization of the PRV program provides multi-year policy certainty and a monetizable voucher that can deliver significant non-dilutive funding upon sale. Absent a PRV-like mechanism, UK ...

Sentynl holds an exclusive U.S. commercialization option for AATD-LD, while securing global manufacturing rights; Mereo retains commercial rights outside the U.S. and leads Phase III execution.

In July of this year, Krieger Scientific issued a release addressing the increase in 303 drug warning letters issued by FDA. In 2025, as new leadership took over the agency, FDA sent 303 drug warning ...

Consideration includes $820 million upfront and up to $500 million in approval and sales milestones, with financing expected from cash on hand and existing credit facilities. ABS-1230 is a ...

In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva ...

Last week, reports emerged of a potential merger between AstraZeneca and Bristol Myers Squibb. While a senior source reportedly debunked these rumors days later, the news caused an uproar across the ...

We have been telling ourselves a story about pharma communications for the past 20 years. The story goes like this: Global ...

Even products with a competitive advantage underperform three-year consensus targets 29% of the time; product superiority ...

Such enterprises will be defined not only by breakthrough therapies but also by agile leadership, AI-enabled transformation and patient-centered operating models that accelerate innovation into ...

FDA authorization covers adults ≥50, positioning mFLUSIVA as Moderna’s first mRNA influenza vaccine and expanding its US ...

Rumored tie-up implies acquirer skepticism versus target premium, with AstraZeneca shares falling sharply while BMS rose, reflecting concerns about value transfer and integration risk. A major ...